

Reference Number: FOI202223/235
From: Commercial
Date: 15 August 2022
Subject: new biologic medications within dermatology; no. of patients treated with a list of drugs in July 2022

Q1 I am analysing the usage of new biologic medications within dermatology. Could you please tell me how many patients were treated in July 2022 (or latest available month) by the dermatology department with the following drugs:

- a. Abrocitinib (Cibinqo)
- b. Baricitinib (Olumiant)
- c. Bimekizumab (Bimzelx)
- d. Brodalumab (Kyntheum)
- e. Dupilumab (Dupixent)
- f. Ixekizumab (Taltz)
- g. Risankizumab (Skyrizi)
- h. Guselkumab (Tremfya)
- i. Secukinumab (Cosentyx)
- j. Tildrakizumab (Ilumetri)
- k. Tralokinumab (Adtralza)
- l. Upadacitinib (Rinvoq)
- m. Ustekinumab (Stelara)

- A1
- a. Zero
 - b. Zero
 - c. Zero
 - d. Zero
 - e. 12
 - f. Zero
 - g. Zero
 - h. Zero
 - i. Zero
 - j. Zero
 - k. Zero
 - l. 1
 - m. Zero